MET amplification in metastatic colorectal cancer: an acquired response to EGFR inhibition, not a de novo phenomenon
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
// Kanwal Raghav 1 , Van Morris 1 , Chad Tang 2 , Pia Morelli 1 , Hesham M. Amin 3 , Ken Chen 4 , Ganiraju C. Manyam 4 , Bradley Broom 4 , Michael J. Overman 1 , Kenna Shaw 5 , Funda Meric-Bernstam 6 , Dipen Maru 3 , David Menter 1 , Lee M. Ellis 7 , Cathy Eng 1 , David Hong 6 , Scott Kopetz 1 1 Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA 2 Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA 3 Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA 4 Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA 5 Sheikh Khalifa Bin Zayed Al Nahyan Institute of Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA 6 Department of Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA 7 Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA Correspondence to: Scott Kopetz, email: skopetz@mdanderson.org Keywords: amplification, MET, circulating-free DNA, fluorescence in situ hybridization, colorectal cancer Received: March 14, 2016 Accepted: May 05, 2016 Published: July 13, 2016 ABSTRACT Background: MET amplification appears to be a predictive biomarker for MET inhibition. Prior studies reported a MET amplification rate of 9–18% in metastatic colorectal cancer (mCRC) but do not differentiate increased gene copy numbers due to chromosomal level aberrations from focal gene amplifications. Validation of MET amplification rate in mCRC is critical to this field. Results: In tumor tissue-based analyses, overall MET amplification rate was 1.7% (10/590). MET amplification was seen in 0/103 (0%), 4/208 (1.9%) and 6/279 (2.2%) cases, in cohorts 1, 2 and 3, respectively. Rate of MET amplification in cfDNA of cohort 4 patients refractory to anti-EGFR therapy ( n = 53) was 22.6% (12/53) and was significantly higher compared to patients not exposed to anti-EGFR therapy ( p < 0.001). Materials and Methods: We analyzed MET amplification in mCRC ( n = 795) using different methods across multiple cohorts. Cohort 1 ( n = 103) and 2 ( n = 208) included resected liver metastases and tumor biopsies, respectively, tested for MET amplification using fluorescence in-situ hybridization [amplification: MET/CEP7 ratio ≥ 2.0]. Using another tissue-based approach, cohort 3 ( n = 279) included tumor biopsies sequenced with HiSeq (Illumina) with full exome coverage for MET [amplification: ≥ 4 copies identified by an in-house algorithm]. Using a blood-based approach by contrast, cohort 4 ( n = 205) included patients in whom the full exome of MET in circulating-free DNA (cfDNA) was sequenced with HiSeq. Conclusions: Contrary to prior reports, in this large cohort, MET amplification was a rare event in mCRC tissues. In plasma by stark contrast, MET amplification identified by cfDNA occurred in a sizable subset of patients that are refractory to anti-EGFR therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lanman, R. B., Mortimer, S. A., Zill, O. A., Sebisanovic, D., Lopez, R., Blau, S., Collisson, E. A., Divers, S. G., Hoon, D. S. B., Kopetz, E. S., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0140712 · Cited by 695 · cited 1×
“[19] All testing was performed in CLIA-certified laboratories (Table 1).”
MethodAmplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer
Bardelli, A., Corso, S., Bertotti, A., Hobor, S., Valtorta, E., Siravegna, G., Sartore-Bianchi, A., Scala, E., Cassingena, A., Zecchin, D., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0558 · Cited by 657 · cited 2×
“[8] Consequently, MET amplification could potentially serve as a useful predictive biomarker of MET inhibitor response in mCRC clinical trials.”
Background
Cited by
Dekker, E., Tanis, P. J., Vleugels, J. L. A., Kasi, P. M., & Wallace, M. B. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32319-0 · Cited by 4,974
MET-dependent solid tumours — molecular diagnosis and targeted therapy
Guo, R., Luo, J., Chang, J., Rekhtman, N., Arcila, M., & Drilon, A. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0377-z · Cited by 323
Genomic Landscape of Cell-Free DNA in Patients with Colorectal Cancer
Strickler, J. H., Loree, J. M., Ahronian, L. G., Parikh, A. R., Niedzwiecki, D., Pereira, A. A. L., McKinney, M., Korn, W. M., Atreya, C. E., Banks, K. C., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1009 · Cited by 295
Self-citationKitamura, N., Sento, S., Yoshizawa, Y., Sasabe, E., Kudo, Y., & Yamamoto, T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010240 · Cited by 256
Raghav, K., Loree, J. M., Morris, J. S., Overman, M. J., Yu, R., Meric-Bernstam, F., Menter, D., Korphaisarn, K., Kee, B., Muranyi, A., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.18.00226 · Cited by 132
Self-citationMolecular Landscape of ERBB2/ERBB3 Mutated Colorectal Cancer
Loree, J. M., Bailey, A. M., Johnson, A. M., Yu, Y., Wu, W., Bristow, C. A., Davis, J. S., Shaw, K. R., Broaddus, R., Banks, K. C., et al. (2018) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djy067 · Cited by 68
Self-citationClinical Utility of Analyzing Circulating Tumor DNA in Patients with Metastatic Colorectal Cancer
Nakamura, Y., & Yoshino, T. (2018) · The Oncologist · doi:10.1634/theoncologist.2017-0621 · Cited by 61
Anti-EGFR Therapy in Metastatic Colorectal Cancer: Identifying, Tracking, and Overcoming Resistance
Leite, L. F., Noronha, M. M., de Menezes, J. S. A., da Conceição, L. D., Almeida, L. F. C., Cappellaro, A. P., Belotto, M., Biachi de Castria, T., Peixoto, R. D., & Megid, T. B. C. (2025) · Cancers · doi:10.3390/cancers17172804 · Cited by 32
“Despite this, survival outcomes were encouraging, with a median PFS of 2.6 months and a median OS of 9.2 months [90].”
InfluentialScott, A. J., Basu Mallick, A., Dotan, E., Cohen, S. J., Gold, P. J., Hochster, H. S., Subramaniam, S., Barzi, A., Watts, G. S., Blatchford, P. J., et al. (2022) · Cancer Research Communications · doi:10.1158/2767-9764.crc-22-0169 · Cited by 18
Jia, J., Morse, M. A., Nagy, R. J., Lanman, R. B., & Strickler, J. H. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00305 · Cited by 17
Metadata
- Authors
- Raghav, K., Morris, V., Tang, C., Morelli, P., Amin, H. M., Chen, K., Manyam, G. C., Broom, B., Overman, M. J., Shaw, K., Meric-Bernstam, F., Maru, D., Menter, D., Ellis, L. M., Eng, C., Hong, D., & Kopetz, S.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2016-07-13
- Volume
- 7
- Issue
- 34
- Pages
- 54627-54631
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2461784407
- Cited by
- 77
- References
- 2
- FWCI
- 4.17
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.